This article is more than 5 years old. Information may no longer be current.

VIDEO: IMCgp100 a promising option for uveal melanoma treatment, speaker says

ByRichard Carvajal, MD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HONOLULU — Early studies have shown IMCgp100 (Immunocore), a bispecific T-cell redirector, to be “extremely promising” for the treatment of uveal melanoma, Richard Carvajal, MD, said at the Association for Research in Vision and Ophthalmology meeting here.